This is an open access article under the terms of the Creat ive Commo ns Attri bution-NonCo mmercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. CRC were enrolled in the second-phase examination to monitor the emergence of alterations occurring during treatment with epidermal growth factor receptor (EGFR)-specific antibodies. Using LFIMA, we effectively captured CTC (median number of CTC, 14.5 cells/mL) from several types of cancer and detected missense mutations via NGS of CTC and ctDNA. We also detected time-dependent genetic alterations that appeared during anti-EGFR therapy in CTC and ctDNA from CRC patients. The
| INTRODUC TI ON
Genetic and phenotypic variations occur between tumors involving different tissues and cell types as well as between individuals with the same tumor type. [1] [2] [3] To enhance understanding of these phenomena, longitudinal tumor sampling approaches will be essential to elucidate the impact of tumor heterogeneity on cancer evolution. gatekeeper mutation, which confers resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors. 6, 7 Furthermore, next-generation sequencing (NGS) of breast cancer CTC revealed significant interpatient heterogeneity that could be monitored over time. 8, 9 Among current technologies for CTC detection, the only one cleared by the FDA for use in clinical settings is the CellSearch system. In this system, CTC are isolated with an antibody against the epithelial cell adhesion molecule (EpCAM) as a biomarker. However, conventional methods based on detection of EpCAM carry the risk of missing the most aggressive CTC subpopulations due to epithelialmesenchymal transition (EMT), potentially leading to underestimation of the total number of actual CTC present in the bloodstream.
To overcome this drawback, a label-free inertial microfluidics approach (LFIMA) was recently developed to enrich CTC from blood samples. 10 This system enables efficient isolation of CTC without affinity purification of epithelial biomarkers, thereby avoiding underestimation of CTC subpopulations exhibiting downregulation of EpCAM expression.
Here, we established a method using LFIMA with NGS for the analysis of genomic alterations in CTC isolated from patients with head and neck cancer (HNC) or gastrointestinal (GI) cancer. In addition, we carried out blood-based molecular profiling to identify actionable drug targets, monitor drug resistance, and track tumor dynamics using CTC and ctDNA from patients with metastatic colorectal cancer (CRC). 
| MATERIAL S AND ME THODS

| Patients and peripheral blood samples
| Immunofluorescence cytochemistry
Circulating tumor cell slides were prepared using a cyto-spin device and stored at −80°C. Cells were fixed with 4% paraformaldehyde for 10 minutes at room temperature and permeabilized with 0.1% Triton X-100 (Sigma-Aldrich). The cells were then incubated with anti-pan CK rabbit polyclonal antibody (NICHIREI BIOSCIENCE), followed by incubation with anti-rabbit IgG Alexa Fluor 488 (Thermo Fisher Scientific). 
| DNA extraction and quantification
DNA from CTC was prepared immediately after isolation, and wholegenome amplification (WGA) was carried out using a REPLI-g Single Cell Kit (Qiagen GmbH). The amplified DNA was purified using an Agencourt AMPure XP system (Beckman Coulter). Fragmentation of the output DNA of the WGA reaction was assessed using a TaqMan RNase P Detection Reagents Kit and FFPE DNA QC assay (Thermo Fisher Scientific).
A five-point standard curve was prepared using human control genomic DNA (included in the TaqMan RNase P Detection Reagents Kit), and absolute DNA concentrations were determined against the standard curve using real-time PCR. 
| Targeted NGS
Library preparation was performed using 20 ng of CTC DNA, ctDNA, Chef system (Thermo Fisher Scientific). Sequencing was performed on an Ion S5XL System using a 530 chip (Thermo Fisher Scientific).
F I G U R E 1 Flow diagram of the optimized protocol for detecting genomic alterations in circulating tumor cells (CTC) and ctDNA, and immunofluorescence cytochemistry of isolated CTC. A, Blood from patients (up to 2 × 5 mL of peripheral blood) was collected using EDTA vacutainers. One collection tube of hemolyzed whole blood was diluted 3-fold. CTC were isolated from the blood using a label-free inertial microfluidics approach (LFIMA). ctDNA and buffy coat DNA were isolated from the other collection tube. Targeted next-generation sequencing was performed using the extracted DNA. B, Fluorescence image of isolated CTC stained for cytokeratin (green). NGS, nextgeneration sequencing; WGA, whole-genome amplification 
| Sequencing data analysis and variant calling
Sequencing data were assessed using Torrent Suite software, version 5.6. Variants were called using ion-plugin-coverageAnalysis, version 5.6.0.1, and ion-plugin-variantCaller, version 5.6.0.4. Single nucleotide variants, insertions and deletions were annotated using the Ion Reporter software, version 5.6 (Thermo Fisher Scientific). The allele frequency threshold was set to 5%, and minimum coverage per target amplicon was set to 250× to report de novo mutations.
| RE SULTS
| Development of efficient analytical methods using DNA extracted from liquid biopsy samples from patients in the first-phase examination
The study workflow is summarized in Figure 1A . To develop efficient methods for the analysis of mutations in CTC collected from patient blood samples, we optimized the CTC capture method using an LFIMA from the first examination phase, which consisted of 30 patients with HNC, OC, GC and CRC.
Baseline characteristics of the 10 patients with HNC are shown in Table 1 . The median age was 70 years (range, 42-80 years). The tumor locations were as follows: 5 in the oral cavity (50%), 1 in the salivary glands (50%), 3 in the pharynx (30%) and 1 in the cervical esophagus (10%). Nine patients had squamous cell carcinoma, and 1 patient had adenoid cystic carcinoma. The number of patients at clinical stage II, III and IV was 3 (30%), 1 (10%) and 6 (60%), respectively. Baseline characteristics of the 20 patients with advanced GI cancers, which consisted of 8 (40%) patients with OC, 1 with GC (5%) and 11 with CRC (55%), are shown in Table 2 . The median age was 61.5 years (range, 46-73 years). Eastern Cooperative Oncology
Group performance status at consent of 0, 1 and 2 were 9 (45%), 10 (50%) and 1 (5%), respectively. Of these patients, 14 had recurrence.
The number of patients with prior chemotherapy lines was 3 (15%) with 1 line, 5 (25%) with 2 lines and 3 (15%) with greater than 4 lines.
| Genomic profiling of circulating tumor cells and ctDNA using next-generation sequencing in the first-phase examination
To determine the number of CTC, we carried out immunofluorescent analyses with anti-pan keratin antibody ( Figure 1B ). Of the patients enrolled in the first-phase examination, the number of CTC was determined for 27 patients (Figure 2A and S1). The median number of CTC was 14.5/mL (range, 3-133/mL).
The results of genomic profiling by NGS of HNC CTC samples are shown in Figure 2A . Details regarding CTC mutation profiles, allele frequencies and coverages are shown in Table S2 . Missense mutations were detected in 4 out of 10 (40%) HNC patients; these included mutations in EGFR and SMAD4 (n = 1), TP53 (n = 1), RB1 (n = 1) and CDKN2A (n = 1). The missense mutations in EGFR and SMAD4 were detected in the same case of HNC. In contrast, the missense mutations in TP53, RB1 and CDKN2A were detected in different cases.
The most frequent missense mutations in CTC from GI cancer were detected in ALK, GNAQ, RB1 and SMAD4, and these mutations occurred in 4 cases (20%). Moreover, missense mutations in APC, EGFR, RET and SMARCB1 were detected in 3 cases (15%). The most frequent missense mutations in cases of OC and CRC occurred in SMARCB1 (3/8, 37.5%) and RB1 (3/11, 27.3%), respectively. The missense mutations analyzed in this first-phase examination of CTC occurred in 4 cases of OC (4/8, 50%), 1 case of GC (1/1, 100%) and 4 cases of CRC (4/11, 36.4%).
Of the 30 patients enrolled in first-phase examination, ctDNA was obtained from 28 patients to confirm mutations in cells circulating in the plasma using NGS. Details regarding ctDNA mutation profiles, allele frequencies and coverages are shown in Table S2 . The mutation profile is shown in Figure 2B . Missense mutations in ALK and MET were detected in 1 case of HNC; however, these missense mutations could not be detected in the remaining 9 cases of HNC.
The most frequent missense mutations in GI cancers occurred in TP53, and these were detected in 8 cases of GI cancer (44.4%). The most frequent missense mutations in both OC and CRC occurred in TP53, and these were detected in 4 cases of OC (4/8, 50%) and 4 cases of CRC (4/9, 44.4%). Nonsense mutations in APC were detected in 2 cases of CRC. A frameshift deletion in APC was detected in 1 case of CRC; in addition, a frameshift insertion in APC was detected in a case of OC. No missense/nonsense or frameshift-insertion/-deletion mutations were detected in 3 cases of OC (3/8, 37.5%) and 2 cases of CRC (2/9, 22.2%), respectively. 
| Combination analysis of genomic mutation profiles obtained from circulating tumor cells and ctDNA
The results of genomic mutation profiling of CTC and ctDNA ( Figure 2A ,B) suggested that the genetic mutational concordance between profiles of CTC and ctDNA was not high. As tumor heterogeneity suggested that the CTC and ctDNA samples exhibited different profiles, we conducted a combination analysis ( Figure 2C ).
The combination analysis improved the rate of genomic alteration detection compared to the assays of CTC or ctDNA alone.
The combination analysis detected missense mutations in 5 cases of HNC (5/10, 50%) and 15 cases of GI cancer (15/18, 83.3%). The same amino acid changes were detected in 6 of 28 cases in which both CTC and ctDNA were analyzed (Tables S2 and S3 ). Details of associations between genomic alterations detected in CTC and ctDNA are shown in Figure 2D (HNC) and E (GI cancer). anti-EGFR therapy for metastatic CRC ( Figure 3A) . We examined blood samples from 7 patients with metastatic CRC who received anti-EGFR therapy (Table S4 ). These patients were monitored at 2 time points: before initiation of anti-EGFR therapy and at disease progression. Details regarding mutation profiles, allele frequencies and coverages are shown in Table S5 . In patients 1 and 3, genomic alterations emerged in both CTC and ctDNA with disease progression. In patient 7, a nonsense mutation in PIK3CA (p.D84*) was detected in the CTC analysis during progression after irinotecan and panitumumab therapy.
Interestingly, genomic alterations were detected in DNA extracted from CTC and/or ctDNA in all cases examined.
Representative baseline and disease progression CT images are shown in Figure 3B . 
TA B L E 2 Clinicopathologic characteristics of gastrointestinal cancer patients in the first examination phase
F I G U R E 2 Targeted next-generation sequencing and combination analysis of genomic alterations using circulating tumor cells (CTC)
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Because the number of CTC in the bloodstream is extremely low in comparison with other normal hematopoietic cells, WGA methods are generally required for analyzing NGS data for DNA obtained from CTC. WGA strategies are known to introduce artifacts and errors in variation detection studies. 16 Recently, the results of NGS analyses of CTC using WGA methods have been reported. Multiple displacement amplification technology was developed for analyzing genetic alterations from extremely small amounts of DNA extracted from single cells. The accuracy of multiple displacement amplification technology has been evaluated in terms of its reliability in WGA using CTC. 12, 17 To confirm the reliability of WGA, we assessed the fragmentation of amplified CTC DNA. No fragmentation of CTC DNA was detected. Thus, experiments involving WGA were deemed reliable because the method was the same for all CTC analyses.
We optimized the efficiency of a method for NGS analysis of CTC DNA using patient samples with multiple displacement amplification technology.
Molecular and cellular heterogeneity are hallmarks of cancer that have important impacts on the diagnosis and treatment of tumors. 18 A previous study showed that the degree of intratumor heterogeneity can be highly variable, with 0 to >8000 coding mutations found to be heterogeneous within primary tumors or between primary and metastatic or recurrent sites. 19 Liquid biopsy is an essential tool for non-invasive real-time monitoring of cancer and also enables characterization of tumor heterogeneity because blood carries DNA derived from cancer cells located at distinct metastatic sites, in contrast to single-tissue biopsies. 20 CTC and ctDNA may represent a molecular proxy of the overall disease. In this study, when comparing mutations detected in CTC and ctDNA from patients with HNC and CRC, we found that in some blood samples, CTC exhibited mutations that were not detected in ctDNA, whereas in others, ctDNA exhibited mutations that were not detected in CTC. This suggests that CTC and ctDNA exhibit heterogeneity, and therefore, both must be evaluated in the clinical setting to enable optimal surveillance of disease progression and treatment selection. In this study, NGS data revealed that the same genetic alteration could be detected in data obtained from CTC and ctDNA using multiple displacement amplification technology. However, we found that the genetic alteration profiles were not perfectly correlated between CTC and ctDNA.
These data suggest that CTC and ctDNA exhibit unique genetic alteration profiles. In other words, using a combination assay involving CTC and ctDNA could increase the sensitivity of detecting genetic alterations without decreasing the specificity, thus contributing to the establishment of precision medicine for cancer.
Considerable recent attention has focused on the biological heterogeneity of CTC. However, in this study, we did not assess the heterogeneity of CTC because the technique utilizing a label-free inertial microfluidics approach enriched CTC in bulk according to cell size, and we carried out WGA immediately after isolation. In addition, to predict the sensitivity of tumors to molecular therapies, the mutation status of a majority of the tumors must be known. NGS analysis of the genome of bulk CTC could facilitate better predictions of the efficacy of personalized molecular targeted therapies compared with analyses of single CTC.
Anti-EGFR therapy, either alone or in combination with chemotherapy, is the standard treatment for patients with RAS wild-type metastatic CRC. [21] [22] [23] [24] [25] It has become apparent that RAS mutations are correlated with resistance to anti-EGFR therapy, and the presence of RAS mutations accounts for approximately 50%-60% of patients with metastatic CRC refractory to anti-EGFR therapy. 26 In addition to mutations in RAS, mutations in BRAF and PIK3CA can induce constitutive activation of the EGFR and subsequent intracellular signaling, ultimately leading to drug resistance. [27] [28] [29] Several studies have detected these mutations in CTC and ctDNA isolated from patients with CRC. [30] [31] [32] We also detected genomic alterations in KRAS, NRAS, and PIK3CA in CTC and ctDNA using targeted NGS in patients resistant to anti-EGFR therapy, as described in previous reports. In liquid biopsy of CTC and ctDNA, codon 61 mutations in KRAS and NRAS that were detected in our study are more frequently observed after CRC patients have acquired resistance to anti-EGFR therapy than before starting the anti-EGFR therapy.
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More than 80% of mutations detected in PIK3CA have been reported in 2 hotspots, the helicase domain of exon 9 and the kinase domain in exon 20, suggesting that these mutations can be used to predict response to treatment with anti-EGFR therapy.
27
The exon 1 mutation we detected in CTC was very infrequent, and its importance and function remain incompletely understood. As for other genes, mutations in FBXW7 and SMAD4 were frequently detected, and these mutations, which are located in the same domain as the mutation we reported in this study, are involved in acquired resistance to anti-EGFR therapy. 33, 34 Our data, which were obtained from a relatively small number of samples, showed that further study is needed to determine whether genetic information for CRC cells obtained from liquid biopsy of patients resistant to anti-EGFR therapy could enhance efforts to overcome drug resistance.
However, this study has some limitations. First, our study consisted of a small number of samples. The results thus need to be validated in a prospective manner with a sufficient sample size.
Second, CTC were defined as cytokeratin-positive in this study.
Recently, CTC have been distinguished from other cells present in the blood based on being: (i) nuclear positive; (ii) cytokeratin positive; and (iii) CD45 negative. 35 We previously stained cells for these markers to identify CTC; however, it is now possible to distinguish CTC morphologically. Indeed, we reported the untargeted molecular profiling of single CTC obtained from patients with gastric cancer and colorectal cancer using live single-cell mass spectrometry integrated with microfluidics-based cell enrichment techniques.
36
In that study, we detected CTC based on CD45 staining and morphology and demonstrated clear differences in the metabolomics profiles of CTC and leucocytes. The present study was not a single-cell analysis of CTC but rather a mutational analysis of CTC.
Therefore, we employed immunostaining with an anti-cytokeratin antibody rather than anti-CD45 antibody. Third, we did not assess the concordance of gene mutations between primary tumor tissues and liquid biopsy sample because almost all cases were advanced stages or recurrences, and the acquisition of biopsy specimens from patients was difficult in the clinical setting at the timely manner.
However, whether the tumor mutation profile obtained from tumor biopsy samples truly reflects tumor heterogeneity is unclear, 37, 38 and in the case of surgical specimens, it may be difficult to compare the gene mutation status of liquid biopsy samples with that of surgical specimens, given that the biological behavior of tumor cells can change moment to moment in response to selective pressures associated with cancer therapies, and the clonal revolution occurred in primary tumors. 39 Therefore, by comparing the gene mutation status of liquid biopsy samples and responsiveness to specific cancer therapies, we aim to establish biomarkers that predict responsiveness based on the gene mutation profile obtained from liquid biopsy samples without being influenced by the mutation profile of the primary tumors.
In summary, we optimized the efficiency of a platform for capturing CTC using an LFIMA and revealed the importance of both CTC and ctDNA as diagnostic tools. In addition, our data suggest that both CTC and ctDNA can be used to closely monitor the emergence of molecular changes in patients with metastatic CRC.
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